AU7370798A - Compositions and methods of therapy for igf-i-responsive conditions - Google Patents

Compositions and methods of therapy for igf-i-responsive conditions

Info

Publication number
AU7370798A
AU7370798A AU73707/98A AU7370798A AU7370798A AU 7370798 A AU7370798 A AU 7370798A AU 73707/98 A AU73707/98 A AU 73707/98A AU 7370798 A AU7370798 A AU 7370798A AU 7370798 A AU7370798 A AU 7370798A
Authority
AU
Australia
Prior art keywords
igf
therapy
gag
compositions
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73707/98A
Other languages
English (en)
Inventor
Alfredo Gorio
Eugenio E. Muller
Bruce F Scharschmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU7370798A publication Critical patent/AU7370798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU73707/98A 1997-05-06 1998-05-06 Compositions and methods of therapy for igf-i-responsive conditions Abandoned AU7370798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI97A1042 1997-05-06
IT97MI001042A IT1291307B1 (it) 1997-05-06 1997-05-06 Composizione farmaceutica atta al trattamento delle patologie neurodegenerative
PCT/US1998/009273 WO1998050062A1 (en) 1997-05-06 1998-05-06 Compositions and methods of therapy for igf-i-responsive conditions

Publications (1)

Publication Number Publication Date
AU7370798A true AU7370798A (en) 1998-11-27

Family

ID=11377071

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73707/98A Abandoned AU7370798A (en) 1997-05-06 1998-05-06 Compositions and methods of therapy for igf-i-responsive conditions

Country Status (7)

Country Link
EP (1) EP1015019B1 (enExample)
JP (1) JP2002507193A (enExample)
AT (1) ATE293990T1 (enExample)
AU (1) AU7370798A (enExample)
DE (1) DE69829982T2 (enExample)
IT (1) IT1291307B1 (enExample)
WO (1) WO1998050062A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200127B1 (en) * 1999-07-21 2008-06-25 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0516901A1 (en) * 1991-06-06 1992-12-09 Richard L. Lindstrom Method and apparatus of a serumfree medical solution

Also Published As

Publication number Publication date
EP1015019A1 (en) 2000-07-05
EP1015019B1 (en) 2005-04-27
ITMI971042A0 (enExample) 1997-05-06
IT1291307B1 (it) 1999-01-07
DE69829982D1 (de) 2005-08-18
WO1998050062A1 (en) 1998-11-12
DE69829982T2 (de) 2006-02-23
ITMI971042A1 (it) 1998-11-06
JP2002507193A (ja) 2002-03-05
ATE293990T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
AU3435497A (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
YU37301A (sh) Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa
NZ502358A (en) Hydrogel composition comprising a biologically active substance combined with a macromer
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
DE69940674D1 (de) Orale verabreichung von adenosin analogen
NZ333380A (en) 6-O-methylerythromycin A crystal form I (clarithromycin) and preparation thereof
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IE863279L (en) Plasminogen activator composition
AU1890295A (en) Piperidines and pyrrolidines
CA2170255A1 (en) Pharmaceutical Composition for Immunoenhancement Therapy
DK0460062T3 (da) Huperzin A-analoger
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
HU9502087D0 (en) Novel colon- or ileum-specific steroid derivatives
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
AU2001261516A1 (en) Semi-solid delivery vehicle and pharmaceutical compositions
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf
TW200505436A (en) Modified release pharmaceutical compositions and the processes for preparing them
AU8239298A (en) Nucleotide-comprising composition
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
EP1023901A4 (en) MEDICINES FOR HEPATITIS C AND THE USE THEREOF
FI853228A7 (fi) Uudet -butyrolaktaamit, niiden farmaseuttisesti aktiiviset koostumukset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkeaineina.
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase